A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Mark Herzberg is a Professor of Clinical Haematology involved in clinical trials for patients with blood cancers, particularly lymphoma, leukaemia, and myeloma, in Australia and New Zealand.
Hodgkin lymphoma is a common cancer with varied symptoms, and treatment typically involves chemotherapy and sometimes radiation therapy.
Approximately 800 Australian patients are diagnosed with advanced stage Hodgkin lymphoma each year, with staging determined through imaging and blood tests.
Advanced stage Hodgkin lymphoma is treated with outpatient combination chemotherapy using two major regimens (ABVD and escalated BEACOPP) worldwide, with a global clinical trial involving nine cooperative groups in nine countries and 1500 patients.
The ALLG contributed 115 patients across 16 sites in Australia and New Zealand to a groundbreaking clinical trial.
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen incorporating a new drug, Brentuximab Vedotin.
Patients experienced fewer side effects, such as anaemia, low platelet counts, peripheral neuropathy, and gonadal toxicity, while preserving fertility, with the modified BrECADD regimen in the treatment of advanced stage Hodgkin lymphoma.
Most patients with advanced stage Hodgkin lymphoma remained disease-free after three years of treatment, with a significant reduction in toxicity and shorter duration of treatment, allowing them to resume normal life and work sooner.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
You Might also like
-
Driven by purpose
Dr Joe DusseldorpDr Joe Dusseldorp is an Australian surgeon who was first in the country to implant custom 3D printed ears in a number of young Australian children born with a congenital abnormality called microtia. His family ancestry is unique in having 5 generations of medical doctors. Driven by a deeper purpose in treating patients, Dr Dusseldorp’s segment continues Australian Health Journal’s People in Health Care series.
-
Entering The New Health Frontier
A new parliamentary report ‘The New Frontier: Delivering better health for all Australians’ is recommending significant reforms to the health care system to ensure Australians have better and faster access to the wave of new medicines and technologies.
The bipartisan report makes 31 recommendations to reform Australia’s system for the regulation and reimbursement with the hope that patients will receive faster access to the latest medicines and technologies.
-
Message from former Australian Health Minister Hon Greg Hunt
The Honourable Greg Hunt served in the Australian Government as Minster for Health and Aged Care from 2017, previously as Industry, Innovation and Science Minister and before that the Environment Minister.
Elected as the Member for Flinders in 2001, Greg announced his retirement from politics late 2021 and in 2022, ahead of the Federal Election, having completed 20 years as a public servant.
Australian Health Journal recently caught up with Greg in a relaxed interview at his home in the Mornington Peninsula, Victoria to hear how a 9 month sabbatical has allowed him to focus on family, fitness and future. This has even included some “brutal spin cycle classes!”.